Walgreens and Freenome have announced a multi-year relationship to advance clinical studies of Freenome’s blood-based tests for the early detection of cancer. Walgreens will utilize its resources to engage diverse patient populations in Freenome’s multi-cancer research program.
Working together with technology provider Curebase, Walgreens will initially recruit patients across diverse populations for Freenome’s Sanderson Study, which aims to evaluate blood-based early detection tests for multiple cancers. Using Curebase’s platform, Walgreens will deliver targeted outreach to potentially eligible patients and caregivers of all backgrounds via text, email, or in-person consultation at the pharmacy. After completing a pre-screen, eligible patients are invited to enroll in the study. Walgreens healthcare providers will then perform a single blood draw at one of the company’s clinical trial locations and conduct a telehealth patient follow-up one year after their participation.
The Sanderson Study will enroll approximately 8,000 participants through its clinical study partner network, which includes Walgreens.
Walgreens and Freenome will also work together on building risk-prediction models and population health software. The aim is to help close existing care gaps and identify people who are eligible and stand to benefit from standard-of-care cancer detection testing. Real-world data collected by Walgreens as part of this collaboration will inform the development of new products and services in Freenome’s multi-cancer detection research, including the company’s blood-based colorectal cancer screening test.
Walgreens and Freenome Partner to Increase Diversity in Research Focused on the Early Detection of Cancer. (2023, June 15). Walgreens.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Real-World Data Show 99% Efficacy for Apretude in HIV Prevention with High Adherence, Reduced Stigma
October 16th 2024Real-world data presented at IDWeek 2024 show Apretude (cabotegravir long-acting) is more than 99% effective in preventing HIV infection, with high adherence rates, reduced stigma and anxiety, and broad acceptability.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.